About: Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York
Creator	Zucker, Howard Parker, Monica Barranco, Meredith Chung Phd, Rakkoo Chung, Rakkoo Dr, Holtgrave Drph, Danielle Es, Rosenberg Greene, David Ha, Zucker Hoefer Phd, Dina Hoefer, Jessica Holtgrave Phd, David Holtgrave, Dina Hutton Mph, Brad Hutton, Howard Je, Morne Jm, Tesoriero John, Shu-Yin Kumar, Jessica Kumar, Tomoko Leung, John Lm, Styer Ma, Barranco Ma, Johanne Ma, Leung Mm, Parker Morne, Danielle Morne, Johanne Mph, Meredith Rosenberg Phd, Eli Rosenberg, Eli Rosenthal Mph, Elizabeth Rosenthal, E Rosenthal, Elizabeth Styer, Linda Sy, John Tesoriero, James Udo Phd, Tomoko Udo, Brad Zucker,
Source	Elsevier; Medline; PMC
abstract	PURPOSE: New York State (NYS) is an epicenter of the SARS-CoV-2 pandemic in the United States. Reliable estimates of cumulative incidence in the population are critical to tracking the extent of transmission and informing policies. METHODS: We conducted a statewide seroprevalence study among a 15,101 patron convenience sample at 99 grocery stores in 26 counties throughout NYS. SARS-CoV-2 cumulative incidence was estimated from antibody reactivity by first post-stratification weighting then adjusting by antibody test characteristics. The percent diagnosed was estimated by dividing diagnoses by estimated infection-experienced adults. RESULTS: Based on 1,887 of 15,101 reactive results (12.5%), estimated cumulative incidence through March 29 was 14.0% (95% CI: 13.3-14.7%), corresponding to 2,139,300 (95% CI: 2,035,800-2,242,800) infection-experienced adults. Cumulative incidence was highest in New York City (NYC) 22.7% (95% CI: 21.5-24.0%) and higher among Hispanic/Latino (29.2%), non-Hispanic black/African American (20.2%), and non-Hispanic Asian (12.4%) than non-Hispanic white adults (8.1%, p<.0001). An estimated 8.9% (95% CI: 8.4-9.3%) of infections in NYS were diagnosed, with diagnosis highest among adults ≥55 years (11.3%, 95% CI: 10.4-12.2%). CONCLUSIONS: From the largest US serosurvey to date, we estimated > 2 million adult New York residents were infected through late March, with substantial disparities, although cumulative incidence remained below herd immunity thresholds. Monitoring, testing, and contact tracing remain essential public health strategies.
has issue date	2020-06-17(xsd:dateTime)
bibo:doi	10.1016/j.annepidem.2020.06.004
bibo:pmid	32648546
has license	no-cc
sha1sum (hex)	73ec0ef86bf8d9857de0c2c9869f2bd731f52d56
schema:url	https://doi.org/10.1016/j.annepidem.2020.06.004
resource representing a document's title	Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York
has PubMed Central identifier	PMC7297691
has PubMed identifier	32648546
schema:publication	Ann Epidemiol
resource representing a document's body	covid:73ec0ef86bf8d9857de0c2c9869f2bd731f52d56#body_text
is schema:about of	named entity 'extent' named entity 'diagnosis' named entity 'CUMULATIVE INCIDENCE' named entity 'UNITED STATES' named entity 'population' named entity 'NYS' named entity 'SARS-CoV-2' named entity 'infection' named entity 'cumulative incidence' named entity 'Cumulative incidence' named entity 'infection' named entity '15,000' named entity 'cumulative incidence' named entity 'nucleocapsid' named entity 'random sample' named entity 'immunological' named entity 'antibodies' named entity 'California' named entity 'epidemic' named entity 'March 29' named entity 'cumulative incidence' named entity 'follow-up' named entity 'fingerstick' named entity 'IgG' named entity 'infection' named entity 'Iceland' named entity 'Antibody' named entity 'cumulative incidence' named entity 'American Community Survey' named entity 'epidemic' named entity 'test characteristics' named entity 'Hispanic' named entity 'demographic factors' named entity 'infection' named entity 'infection' named entity 'infection' named entity 'SARS-CoV-2' named entity 'self-isolation' named entity 'IgG' named entity 'cumulative incidence' named entity 'COVID-19'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software